Entering text into the input field will update the search result below

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2020 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET

Company Participants

Tierney Saccavino - EVP, Corporate Communications

Ron Cohen - Founder, CEO, President & Director

Conference Call Participants

Michael Yee - Jefferies

Alexander Thompson - Stifel, Nicolaus & Company

Turner Kufe - JPMorgan Chase & Co.

Philip Nadeau - Cowen and Company

Andrea Tan - Goldman Sachs Group


Welcome to the Acorda Therapeutics First Quarter 2020 Update. [Operator Instructions]. Please be advised that this call is being recorded at the company's request. I will now introduce your host for today's call, Tierney Saccavino, Executive Vice President, Corporate Communications at Acorda. Please go ahead.

Tierney Saccavino

Thank you. Good morning or good afternoon, everyone. Before we begin, let me remind you that our presentation will contain forward-looking statements. Detailed disclosures can be found in our SEC filings, which are public, and we encourage you to refer to those filings. I will now pass the call on to our CEO, Ron Cohen.

Ron Cohen

Starting with the COVID-19 pandemic, this has created an unprecedented challenge for businesses throughout the country and the world. Our top priorities are ensuring the health and safety of Acorda's associates and their families while also continuing to serve the Parkinson's disease in multiple sclerosis communities. Most of our associates are now working from home, with the exception of a small number of employees who are needed to keep our manufacturing facility compliant and manage the operations of our Ardsley offices. Our facilities receive regular deep cleaning. Those associates who need to go in, have access to masks, gloves and hand sanitizer. And we also import social distancing.

We haven't had any interruptions in the supply of our medications, and we currently don't know of any circumstances that would cause a disruption. Our

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About ACOR Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ACOR

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.